0000849146-20-000163.txt : 20201103 0000849146-20-000163.hdr.sgml : 20201103 20201103160743 ACCESSION NUMBER: 0000849146-20-000163 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20201103 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201103 DATE AS OF CHANGE: 20201103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841097796 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35647 FILM NUMBER: 201283559 BUSINESS ADDRESS: STREET 1: 9785 S. MONROE STREET STREET 2: SUITE 300 CITY: SANDY STATE: UT ZIP: 84070 BUSINESS PHONE: 801-432-9000 MAIL ADDRESS: STREET 1: 9785 S. MONROE STREET STREET 2: SUITE 300 CITY: SANDY STATE: UT ZIP: 84070 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 lfvn-20201103.htm 8-K lfvn-20201103
0000849146false00008491462020-11-032020-11-03

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
 FORM 8-K
 ______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2020
 ______________________________
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________
Delaware001-3564790-0224471
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(IRS Employer
Identification No.)
9785 S. Monroe Street, Suite 400
Sandy, Utah 84070
(Address of principal executive offices, including zip code)
(801) 432-9000
(Registrant's telephone number)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, par value $0.0001LFVNThe Nasdaq Stock Market LLC
Title of each classTrading Symbol(s)Name of each exchange on which registered
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 2.02.    Results of Operations and Financial Condition.
On November 3, 2020, the Company issued a press release announcing its financial results for the three months ended September 30, 2020. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.
The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:November 3, 2020By:LIFEVANTAGE CORPORATION

/s/ Steven R. Fife
Name:Steven R. Fife
Title:Chief Financial Officer

EX-99.1 2 earningsreleaseq1fy21.htm EX-99.1 Document
logoa181a.jpg
LifeVantage Announces Financial Results for the
First Quarter of Fiscal 2021
First Quarter Adjusted EPS and Adjusted EBITDA Increased 92% and 43%, respectively
Reiterates Guidance
Salt Lake City, UT, November 3, 2020, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first quarter ended September 30, 2020.
First Quarter Fiscal 2021 Highlights*:
Revenue of $54.8 million, a decline of 2.5% from the prior year period, largely reflecting the lack of an Elite Academy event not replicated during the first quarter of fiscal 2021;
Revenue in the Americas decreased 3.7% and revenue in Asia/Pacific & Europe increased 0.7%;
Total active accounts decreased 3.9% sequentially to 172,000, while declining 5.0% compared to the prior year period. The sequential decline included a 6.8% decline in distributors and a 1.9% decline in customers. Compared to the prior year period, distributors grew 4.6% and customers declined 10.3%;
Earnings per diluted share were $0.17, up 41.7% over the prior year period;
Adjusted earnings per diluted share were up 92.3% to $0.25, compared to $0.13 in the prior year period;
Adjusted EBITDA increased 42.5% compared to the prior year period to $6.7 million;
Repurchased 136,000, or $2.0 million, of common shares; and
Strong balance sheet with $18.0 million of cash and no debt.
* All comparisons are on a year over year basis and compare the third quarter of fiscal 2020 to the third quarter of fiscal 2019, unless otherwise noted.
"We continue to generate strong year over year growth in active distributors both in the U.S. and internationally, while revenue growth was negatively impacted by the timing of our Elite Academy events as last year’s Q1 event was not replicated this year. However, we continue to drive strong adjusted EBITDA growth and nearly doubled adjusted EPS on a year over year basis,” stated LifeVantage Interim Chief Executive Officer and Chief Financial Officer, Steve Fife. “We completed a highly successful virtual convention early in the second quarter of fiscal 2021, launching 6 new flavors of our Axio product line and delivering incremental training and standardized selling tools and systems to our field. We continue to develop additional tools, product videos and messaging to support our distributors social media and standard selling practices. Furthering our growth efforts, we successfully launched our operations in Singapore and expanded our NFR offerings into Malaysia during the first quarter, continuing our expansion across Asia. LifeVantage continues to have a significant international growth opportunity that we believe will remain a core driver of sustainable long-term growth. Additionally, our financial position is one of significant strength, ending the first quarter with $18 million in cash and no debt. We believe we have the resources, the products and the team to drive significant growth in the future and deliver incremental shareholder value. "


logoa181a.jpg
First Quarter Fiscal 2021 Results
For the first fiscal quarter ended September 30, 2020, the Company reported revenue of $54.8 million, a 2.5% decrease over the first quarter of fiscal 2020. Revenue in the Americas for the first quarter decreased 3.7% compared to the first quarter of fiscal 2020 and revenue in the Asia/Pacific & Europe region increased 0.7% compared to the first quarter of fiscal 2020. Revenue for the first quarter of fiscal 2021 was positively impacted $0.2 million, or 0.3%, by foreign currency fluctuations associated with revenue generated in international markets when compared to the first quarter of fiscal 2020.
Gross profit for the first quarter of fiscal 2021 was $45.4 million, or 82.9% of revenue, compared to $47.0 million, or 83.7% of revenue, for the same period in fiscal 2020. The decline in gross margin as a percentage of revenue is primarily due to decreased revenue primarily reflecting the fact that we did not hold an Elite Academy event during the current year period as we did in the prior year same period. Additionally, gross margin was impacted during the current year due to increased shipping to customer expenses and shifts in geographic and product sales mix.
Commissions and incentives expense for the first quarter of fiscal 2021 was $25.6 million, or 46.8% of revenue, compared to $26.8 million, or 47.6% of revenue, for the same period in fiscal 2020. The decrease in commissions and incentives expense as a percentage of revenue is due mainly to the timing and magnitude of investments in our promotional and incentive programs and our red carpet program.
Selling, general and administrative expense (SG&A) for the first quarter of fiscal 2021 was $16.3 million, or 29.7% of revenue, compared to $17.7 million, or 31.5% of revenue, for the same period in fiscal 2020. Adjusted for nonrecurring expenses, which are detailed in the GAAP to non-GAAP reconciliation tables included at the end of this press release, adjusted non-GAAP SG&A expenses for the first quarter of fiscal 2021 were $14.7 million, or 26.8% of revenue, compared to adjusted non-GAAP SG&A expenses for the first quarter of fiscal 2020 of $17.5 million, or 31.0% of revenue. The year over year decrease in non-GAAP SG&A primarily was due to decreased events expenses as a result of no Elite Academy event being held during the current year period.
Operating income for the first quarter of fiscal 2021 was $3.5 million, or 6.4% of revenue, compared to $2.6 million, or 4.6% of revenue, for the first quarter of fiscal 2020. Accounting for non-GAAP adjustments noted previously, adjusted non-GAAP operating income for the first quarter of fiscal 2021 was $5.1 million, or 9.3% of revenue, compared to $2.8 million, or 5.0% of revenue, for the first quarter of fiscal 2020.
Net income for the first quarter of fiscal 2021 was $2.5 million, or $0.17 per diluted share. This compares to net income for the first quarter of fiscal 2020 of $1.8 million, or $0.12 per diluted share. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the first quarter of fiscal 2021 increased 88.5% year over year, to $3.6 million, or $0.25 per diluted share. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the first quarter of fiscal 2020 was $1.9 million, or $0.13 per diluted share.
Adjusted EBITDA increased 42.5% to $6.7 million for the first quarter of fiscal 2021, compared to $4.7 million for the comparable period in fiscal 2020.
Balance Sheet & Liquidity
The Company used $1.1 million of cash from operations during fiscal 2021 compared to using $3.5 million during fiscal 2020. The Company's cash and cash equivalents at September 30, 2020 were $18.0 million, compared to $22.1 million at June 30, 2020. The Company has no debt outstanding at September 30, 2020, and at June 30, 2020. During the first quarter of fiscal 2021, the Company repurchased 136,000 common shares for $2.0 million under its share repurchase program.
Fiscal Year 2021 Guidance
The Company is reiterating its outlook for fiscal 2021, which was initially provided when the Company reported fourth fiscal quarter and full fiscal year 2020 results on August 18, 2020. The Company expects to generate revenue in the range of $240 million to $251 million in fiscal year 2021 and adjusted EBITDA of $25 million to $27 million, with adjusted earnings per share in the range of $0.87 to $0.91, which assumes a full year tax rate of


logoa181a.jpg
approximately 30%. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2021. This guidance reflects the current trends in the business and the Company’s current view as to the impact of the COVID-19 pandemic on its business. However, the impact of the COVID-19 pandemic continues to rapidly evolve and actual results could be adversely affected by further deterioration to the global economic and operating environments as a result of future COVID-19 developments. The Company is not providing guidance for GAAP earnings per diluted share for fiscal 2021 due to the potential occurrence of one or more non-operating, one-time expenses, which the Company does not believe it can reliably predict.
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MDT (4:30 p.m. EDT). Investors interested in participating in the live call can dial (877) 705-6003 from the U.S. International callers can dial (201) 493-6725. A telephone replay will be available approximately two hours after the call concludes and will be available through Tuesday, November 10, 2020, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13711780, or (412) 317-6671 from international locations, and entering confirmation code 13711780.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations or directly at http://public.viavid.com/index.php?id=141906. The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and skin and hair care products, including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2 infused skin care and hair care products, Petandim® for Dogs, Axio® smart energy drink mixes, and the PhysIQ™ weight management system. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected financial performance. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.




logoa181a.jpg
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.

Investor Relations Contacts:

Scott Van Winkle, ICR
(617) 956-6736
scott.vanwinkle@icrinc.com


logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(unaudited)
(In thousands, except per share data)September 30, 2020June 30, 2020
ASSETS
Current assets
Cash and cash equivalents$17,960 $22,138 
Accounts receivable2,342 2,610 
Income tax receivable98 — 
Inventory, net14,798 13,888 
Prepaid expenses and other5,835 5,232 
Total current assets41,033 43,868 
Property and equipment, net7,033 7,170 
Right-of-use assets14,554 956 
Intangible assets, net818 851 
Deferred income tax asset2,418 2,164 
Equity securities2,205 2,205 
Other long-term assets2,151 1,663 
TOTAL ASSETS$70,212 $58,877 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$4,733 $3,521 
Commissions payable7,841 9,219 
Income tax payable603 784 
Lease liabilities2,299 1,184 
Other accrued expenses6,544 10,311 
Total current liabilities22,020 25,019 
Lease liabilities13,160 — 
Other long-term liabilities896 604 
Total liabilities36,076 25,623 
Commitments and contingencies
Stockholders' equity
Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding— — 
Common stock — par value $0.0001 per share, 40,000 shares authorized and 14,238 and 14,313 issued and outstanding as of September 30, 2020 and June 30, 2020, respectively
Additional paid-in capital126,687 126,416 
Accumulated deficit(92,856)(93,307)
Accumulated other comprehensive income304 144 
Total stockholders’ equity34,136 33,254 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$70,212 $58,877 




logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
Three Months Ended September 30,
(In thousands, except per share data)20202019
Revenue, net$54,827 $56,228 
Cost of sales9,398 9,190 
Gross profit45,429 47,038 
Operating expenses:
Commissions and incentives25,633 26,774 
Selling, general and administrative16,299 17,686 
Total operating expenses41,932 44,460 
Operating income3,497 2,578 
Other expense:
Interest expense, net(6)(48)
Other expense, net(141)(80)
Total other expense(147)(128)
Income before income taxes3,350 2,450 
Income tax expense(899)(689)
Net income$2,451 $1,761 
Net income per share:
Basic$0.17 $0.13 
Diluted$0.17 $0.12 
Weighted-average shares outstanding:
Basic14,269 14,009 
Diluted14,695 15,106 



logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Revenue by Region
(unaudited)
Three Months Ended September 30,
(In thousands)20202019
Americas$38,675 71 %$40,181 71 %
Asia/Pacific & Europe16,152 29 %16,047 29 %
Total$54,827 100 %$56,228 100 %
Active Accounts
(unaudited)
As of September 30,
20202019Change from Prior YearPercent Change
Active Independent Distributors (1)
    Americas46,000 68 %44,000 68 %2,000 4.5 %
    Asia/Pacific & Europe22,000 32 %21,000 32 %1,000 4.8 %
        Total Active Independent Distributors68,000 100 %65,000 100 %3,000 4.6 %
Active Customers (2)
    Americas81,000 78 %92,000 79 %(11,000)(12.0)%
    Asia/Pacific & Europe23,000 22 %24,000 21 %(1,000)(4.2)%
        Total Active Customers104,000 100 %116,000 100 %(12,000)(10.3)%
Active Accounts (3)
    Americas127,000 74 %136,000 75 %(9,000)(6.6)%
    Asia/Pacific & Europe45,000 26 %45,000 25 %— — %
        Total Active Accounts172,000 100 %181,000 100 %(9,000)(5.0)%
(1) Active Independent Distributors have purchased product in the prior three months for retail or personal consumption.
(2) Active Customers have purchased product in the prior three months for personal consumption only.
(3) Total Active Accounts is the sum of Active Independent Distributor accounts and Active Customer accounts.



logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA
(Unaudited)
Three Months Ended September 30,
(In thousands)20202019
GAAP Net income$2,451 $1,761 
Interest Expense48 
Provision for income taxes899 689 
Depreciation and amortization(1)
1,132 536 
Non-GAAP EBITDA:4,488 3,034 
Adjustments:
Stock compensation expense464 1,372 
Other expense, net141 80 
Other adjustments(2)
1,629 231 
Total adjustments2,234 1,683 
Non-GAAP Adjusted EBITDA$6,722 $4,717 
(1) Includes $101,000 of accelerated depreciation related to a change in lease term and $335,000 leasehold depreciation on lease abandonment for the three months ended September 30, 2020.
(2) Other adjustments breakout:
      Class-action lawsuit expenses$609 $132 
      Executive team severance expenses
504 — 
      Executive team recruiting and transition expenses 21 — 
      Lease abandonment495 — 
      Other nonrecurring legal and accounting expenses— 99 
Total adjustments$1,629 $231 



logoa181a.jpg

LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS
(Unaudited)
Three Months Ended September 30,
(In thousands)20202019
GAAP Net income$2,451 $1,761 
Adjustments:
Executive team severance expenses, net(1)
54 — 
Executive team recruiting and transition expenses21 — 
Class-action lawsuit expenses609 132 
Other nonrecurring legal and accounting expenses— 99 
Accelerated depreciation related to change in lease term101 — 
Lease abandonment(2)
830 — 
Tax impact of adjustments(433)(65)
Total adjustments, net of tax1,182 166 
Non-GAAP Net Income:$3,633 $1,927 
Three Months Ended September 30,
20202019
Diluted earnings per share, as reported$0.17 $0.12 
Total adjustments, net of tax0.08 0.01 
Non-GAAP adjusted diluted earnings per share$0.25 $0.13 
(1) Net of $450,000 of compensation expense benefit related to unvested stock award reversals
(2) Includes remaining lease rent expense of $495,000 and leasehold depreciation of $335,000


EX-101.SCH 3 lfvn-20201103.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 lfvn-20201103_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 lfvn-20201103_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 lfvn-20201103_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 lfvn-20201103_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 logoa181a.jpg begin 644 logoa181a.jpg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lfvn-20201103_htm.xml IDEA: XBRL DOCUMENT 0000849146 2020-11-03 2020-11-03 0000849146 false 8-K 2020-11-03 LIFEVANTAGE CORP DE 001-35647 90-0224471 9785 S. Monroe Street Suite 400 Sandy UT 84070 801 432-9000 false false false false Common Stock, par value $0.0001 LFVN NASDAQ false XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page
Nov. 03, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 03, 2020
Entity Registrant Name LIFEVANTAGE CORP
Entity Central Index Key 0000849146
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-35647
Entity Tax Identification Number 90-0224471
Entity Address, Address Line One 9785 S. Monroe Street
Entity Address, Address Line Two Suite 400
Entity Address, City or Town Sandy
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84070
City Area Code 801
Local Phone Number 432-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol LFVN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /6 8U$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #U@&-1&B6<6NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y&!R;-I:.G#@8K;.QF;+4UBQUC:R1]^R5>FS*V!]C1TN]/ MGT"-#E+W$9]C'S"2Q70WNLXGJ<.:G8B"!$CZA$ZE,1@M(? MZHA0<;X"AZ2,(@4SL @+D;6-T5)'5-3'"][H!1\^8Y=A1@-VZ-!3 E$*8.T\ M,9S'KH$;8(811I>^"V@68J[^B\GK%M8G M4E[C]"M92>> :W:=_%IO'O=;UE:\XH40!:_W8B7Y@[P7[[/K#[^;L.N-/=A_ M;'P5;!OX=1?M%U!+ P04 " #U@&-1F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M /6 8U%C&E451@0 ,<0 8 >&PO=V]R:W-H965T&UL MG9A1;^HV%,>?[SZ%A?:P2;1)3%K@BB)12N_0;2EKN+W2ICV8Q(#5Q,X4]BF=VT-L:DGQTG"S<\8=FE M2KF$;U9*)\Q 4Z^=+-6<1450$CO4=:^=A G9&@Z*>W,]'*C-9K#?&WG"&@Y2M><#-MW2NH>64*I%(N,R$DD3SU4UKY'V^ MI562KW:QC2Z:;F6B,<\-%:"P<<;'_,XMDK \?=!M%6^ MTP8>7W^HWQ>=A\XL6<;'*OXN(K.Y:?5:).(KEL?F66U_XX<.%8"ABK/B/]GN MG_7]%@GSS*CD$ P$B9#[3_9^2,110(>>"*"' %IP[U]44-XQPX8#K;9$VZ=! MS5X472VB 4Y(6Y7 :/A60)P9CM4;UV0.!1@X!O3L72<\Q-[N8^F)V)EZNR1N MITVH2]U_ASN 4;+0DH46>AV4Y<_1,C,:JO47(MDI)3N%I']"\DZ%.8PA0Q:[ MM+:'>'COXBL"X9<0_GD057)=H5*CB1 M1I@=>>9K89,.C#.6U(+A.@_3^\G+:+88?9F0\=/S'$&[+M&NST$;0^(TB\E4 M1OR=?.6[.CAOV)QQA&.7LG1 M.R<]4QDJG2K-K,>U26!@7!&ER5CED#=(GXIJRXF+WTT0PGY)V#^'\%[$G,SR M9,EU'0BNX;K>1>?JVN\B/)Y;>9U[#M&"O9-I!"44*Q$6B4/X&B3[[H5+J>]W M/8SPR(V]>9+U)XY+];N^*!)?D44FM.(P0#6L%!EO9 MM4?_/^QBJVIA<;"UK)8*%VI:G[S*_CW[) M'XDBD_=PP^2:G]Q>-PC-1L'=Z'>,J3)X>I;!3Q*NUS9+7T#!;*QQI$S6EQ07 M/#G,G*-CJ3WB/S+[QHS$? 5"[F47=/7^U+QO&)46)]6E,G#N+2XWG,$4L _ M]RNES$?#'G[+WRZ&_P!02P,$% @ ]8!C48.II0/4 0 ,@8 T !X M;"]S='EL97,N>&ULU57;BM1 $/V5IC_ GD1V04D"*BP(*@L[#[YVDDK2T#<[ ME3'9K[<[G=NX#*@/HB^3.J>J3YV^3M;C).&I T R*JG[G':(]BUC?=6!XOTK M8T'[3&.5&;0F-,39476&+TS MKVDD?"E70"Y.;E,;5X+8V"5VI(I/0!#M.M%WXHK$L)!&-\D$M><GSVL(Y; RU8@ MY5/8PJ_-E?;8D+@7'^NP#21,=0V]H26,,A$$_:-:U#[(WOV1++'B8O#]X&>C M9_QM, B/#AHQSGALMOZWU)/;ZMQ:.;V3HM4*XMQ_N6&1\74 MPQ6]NJ ;2\)#F-,OX7V5NP=2#D*BT OJ1%V#?G%/O3SRTC_@5_J^OH:&#Q+/ M6S*G>_P9:C&H-UO58UB7I6J//X7W*+F?&^[_$L4/4$L#!!0 ( /6 8U&7 MBKL

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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.lifevantage.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lfvn-20201103.htm earningsreleaseq1fy21.htm lfvn-20201103.xsd lfvn-20201103_cal.xml lfvn-20201103_def.xml lfvn-20201103_lab.xml lfvn-20201103_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lfvn-20201103.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "lfvn-20201103_cal.xml" ] }, "definitionLink": { "local": [ "lfvn-20201103_def.xml" ] }, "inline": { "local": [ "lfvn-20201103.htm" ] }, "labelLink": { "local": [ "lfvn-20201103_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "lfvn-20201103_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "lfvn-20201103.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lfvn", "nsuri": "http://www.lifevantage.com/20201103", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20201103.htm", "contextRef": "ide47dab74df34e55b32da975f7f08ec6_D20201103-20201103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.lifevantage.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20201103.htm", "contextRef": "ide47dab74df34e55b32da975f7f08ec6_D20201103-20201103", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0000849146-20-000163-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000849146-20-000163-xbrl.zip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